GlassScriptPhysician profile
Meaghan Ann Mize
NPI 1568005692
$1,528.22
in general payments reported to CMS, 2019-2025
34 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $181 · 2023: $353 · 2024: $451 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $337.48 | 2021-2023 | Optune |
| Novartis Pharmaceuticals Corporation | $133.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.53 | 2024-2025 | Tagrisso |
| Boston Scientific Corporation | $77.25 | 2022-2023 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $61.14 | 2023-2025 | Orgovyx |
| Emd Serono, INC. | $61.06 | 2021-2025 | |
| Genzyme Corporation | $57.47 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.49 | 2024-2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $47.11 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Mirati Therapeutics, INC. | $43.04 | 2023-2024 | Krazati |
| Merck Sharp & Dohme LLC | $42.82 | 2022-2024 | Keytruda, Welireg |
| Genmab U.S., INC. | $37.86 | 2024 | Epkinly |
| Stemline Therapeutics INC. | $36.85 | 2024-2025 | Orserdu |
| Seagen INC. | $35.97 | 2022-2023 | Adcetris |
| Genentech USA, INC. | $35.58 | 2022-2023 | Tecentriq, Alecensa, Gavreto |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $33.50 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $31.05 | 2024 | Libtayo |
| Daiichi Sankyo INC. | $26.61 | 2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $24.08 | 2025 | |
| Tersera Therapeutics LLC | $23.25 | 2025 | Zoladex |
| Pfizer INC. | $22.95 | 2025 | |
| Eisai INC. | $20.20 | 2022 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $19.88 | 2024 | Sancuso |
| Kite Pharma, INC. | $18.89 | 2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $17.96 | 2023 | Tavalisse, Rezlidhia |
| Celgene Corporation | $17.57 | 2021 | |
| Janssen Biotech, INC. | $17.29 | 2025 | Erleada |
| Kyowa Kirin, INC. | $15.11 | 2024 | Poteligeo |
| Incyte Corporation | $14.56 | 2024 | Jakafi |
| Adc Therapeutics America, INC. | $13.80 | 2025 | |
| Array Biopharma INC | $13.74 | 2021 | |
| Amgen INC. | $12.53 | 2021 | |
| Adaptive Biotechnologies Corporation | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.